![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Avid Bioservices Inc | NASDAQ:CDMO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.44 | 4.26% | 10.76 | 8.30 | 12.50 | 10.782 | 10.111 | 10.60 | 983,091 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
(Exact name of registrant as specified in its charter)
(State of other jurisdiction of incorporation) |
(Commission File Number) |
(IRS
Employer Identification No.) |
(Address of Principal Executive Offices)
Registrant’s telephone number,
including area code:
__________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). | ||
Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12) | ||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b)) | ||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class | Trading Symbol | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On October 23, 2023, Avid Bioservices, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. At the Annual Meeting, of the 63,112,934 shares of the Company’s common stock outstanding (as of the record date of August 25, 2023) and entitled to vote, 54,556,091 shares were present in-person virtually or represented by proxy, representing approximately 86% of the total outstanding shares entitled to vote. The final voting results of each proposal voted on at the Annual Meeting are set forth below. For more information about the proposals set forth below, please refer to the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on August 28, 2023.
Proposal No. 1: Election of Directors
The Company’s stockholders elected each of the seven nominees named below to serve on the Company’s Board of Directors until the Company’s 2024 Annual Meeting of Stockholders. Election of each director required approval by a plurality of the votes cast and thus votes against were not applicable. The votes were as follows:
Nominee |
Votes For |
Votes Withheld |
Broker Non-Votes | |||
Esther M. Alegria, Ph.D. | 45,955,927 | 2,695,187 | 5,904,977 | |||
Joseph Carleone, Ph.D. | 46,710,124 | 1,940,990 | 5,904,977 | |||
Nicholas S. Green | 48,024,167 | 626,947 | 5,904,977 | |||
Richard B. Hancock | 43,015,684 | 5,635,430 | 5,904,977 | |||
Catherine J. Mackey, Ph.D. | 44,810,991 | 3,840,123 | 5,904,977 | |||
Gregory P. Sargen | 45,083,773 | 3,567,341 | 5,904,977 | |||
Jeanne A. Thoma | 43,651,130 | 4,999,984 | 5,904,977 |
Proposal No. 2: Ratification of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024. The votes were as follows:
Votes For | Votes Against | Abstain | ||
53,977,285 | 557,301 | 21,505 |
Proposal No. 3: To Approve, on an Advisory Basis, the Compensation of the Named Executive Officers
The Company’s stockholders approved, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named executive officers as disclosed in the Company’s Definitive Proxy Statement for its 2023 Annual Meeting of Stockholders. The votes were as follows:
Votes For | Votes Against | Abstain | Broker Non-Votes | |||
44,230,126 | 2,260,460 | 2,160,528 | 5,904,977 |
Proposal No. 4: To Determine, on an Advisory Basis, the Frequency of the Advisory Vote on the Compensation of the Named Executive Officers
The Company’s stockholders voted, on an advisory basis, that the frequency of the Company’s named executive officer compensation advisory votes should be every year. The votes were as follows:
One Year | Two Years | Three Years | Abstain | |||
47,301,788 | 75,539 | 1,149,564 | 124,223 |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AVID BIOSERVICES, INC. | |||
Date: October 25, 2023 | By: | /s/ Daniel R. Hart | |
Daniel R. Hart | |||
Chief Financial Officer |
3 |
Cover |
Oct. 23, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Oct. 23, 2023 |
Entity File Number | 001-32839 |
Entity Registrant Name | AVID BIOSERVICES, INC. |
Entity Central Index Key | 0000704562 |
Entity Tax Identification Number | 95-3698422 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 14191 Myford Road |
Entity Address, City or Town | Tustin |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92780 |
City Area Code | (714) |
Local Phone Number | 508-6100 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.001 par value per share |
Trading Symbol | CDMO |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
1 Year Avid Bioservices Chart |
1 Month Avid Bioservices Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions